Oncologix Tech
Market Cap
US$91.4k
Last Updated
2019/09/18 00:01 UTC
Data Sources
Company Financials
Executive Summary
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States.
Snowflake
Fundamentals
Adequate balance sheet with weak fundamentals.
Risks
- Oncologix Tech has significant price volatility in the past 3 months.
- Oncologix Tech's last earnings update was 761 days ago.
- Oncologix Tech is not covered by any analysts.
Share Price & News
How has Oncologix Tech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
OTCPK:OCLG
0.1%
US Healthcare
0.8%
US Market
1 Year Return
0%
OTCPK:OCLG
-8.4%
US Healthcare
1.9%
US Market
OCLG outperformed the Healthcare industry which returned -7.7% over the past year.
OCLG underperformed the Market in United States of America which returned 2.1% over the past year.
Share holder returns
| OCLG | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 0.1% | 0.8% |
| 30 Day | 0% | -1.4% | 3.4% |
| 90 Day | -16.7% | -0.7% | 2.1% |
| 1 Year | 0%0% | -7.0%-8.4% | 4.2%1.9% |
| 3 Year | -50.0%-50.0% | 30.6%25.3% | 46.7%37.2% |
| 5 Year | -97.9%-97.9% | 64.9%55.1% | 62.3%44.5% |
Price Volatility Vs. Market
How volatile is Oncologix Tech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Oncologix Tech undervalued based on future cash flows and its price relative to the stock market?
In this section, we usually try to help investors determine whether Oncologix Tech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Oncologix Tech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Examine Oncologix Tech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Oncologix Tech regulatory filings here.
- Explore potentially undervalued companies in the Healthcare industry.
Future Growth
How is Oncologix Tech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
10.9%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oncologix Tech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Oncologix Tech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Oncologix Tech's filings and announcements here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Oncologix Tech performed over the past 5 years?
0.1%
Historical Healthcare annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Oncologix Tech has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Next Steps
- Examine Oncologix Tech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Oncologix Tech's filings and announcements here.
- Explore strong past performing companies in the Healthcare industry.
Financial Health
How is Oncologix Tech's financial position?
In this section we usually analyse Oncologix Tech's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Oncologix Tech has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
Next Steps
- Take a look at our analysis of OCLG’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
- Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Oncologix Tech's financial data was last updated here.
- Explore more healthy companies in the Healthcare industry.
Dividend
What is Oncologix Tech's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Oncologix Tech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Oncologix Tech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Oncologix Tech has not reported any payouts.
Unable to verify if Oncologix Tech's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Oncologix Tech has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Oncologix Tech's salary, the management and board of directors tenure and is there insider trading?
3.5yrs
Average management tenure
CEO
Michael Kramarz (49yo)
2.8yrs
Tenure
US$80,225
Compensation
Mr. Michael A. Kramarz has been Chairman of the Board and Chief Executive Officer of Oncologix Tech, Inc. since November 24, 2016. Mr. Kramarz has been the Chief Financial Officer of Oncologix Tech, Inc. ( ...
CEO Compensation Analysis
Insufficient data for Michael to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
No earnings data for Oncologix Tech, not possible to compare to compensation.
Management Age and Tenure
3.5yrs
Average Tenure
The tenure for the Oncologix Tech management team is about average.
Insider Trading
No 3 month open market individual insider trading information.
Management Team
Michael Kramarz (49yo)
Chairman of the Board
- Tenure: 2.8yrs
- Compensation: US$80.23k
James Reed
Director of Radiation Science and Radiation Safety Officer
- Tenure: 12.4yrs
- Compensation: US$116.27k
Harold Halman
COO & Director
- Tenure: 2.8yrs
Nikole Jessie
Director of Marketing & Public Relations
- Tenure: 4.2yrs
Board Members
Michael Kramarz (49yo)
Chairman of the Board
- Tenure: 2.8yrs
- Compensation: US$80.23k
Harold Halman
COO & Director
- Tenure: 2.8yrs
Company Information
Oncologix Tech, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Oncologix Tech, Inc.
- Ticker: OCLG
- Exchange: OTCPK
- Founded: 1995
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$91.404k
- Shares outstanding: 914.04m
- Website: https://www.oclghealth.com
Number of Employees
Location
- Oncologix Tech, Inc.
- 1604 West Pinhook Drive
- Suite 200
- Lafayette
- Louisiana
- 70508
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OCLG | OTCPK (Pink Sheets LLC) | Yes | Common Stock | US | USD | Feb 1987 |
Biography
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/18 00:01 |
| End of Day Share Price | 2019/09/17 00:00 |
| Earnings | 2015/05/31 |
| Annual Earnings | 2014/08/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.